MENU

ARQT Stock Arcutis Biotherapeutics (ARQT, $13.4) Aroon Indicator entered an Uptrend on December 18, 2024.

A.I.dvisor
at Tickeron.com
Loading...
ARQT - Arcutis Biotherapeutics
Aroon signal
Bullish Trend
Odds of UP Trend
Tickeron
Aroon signal
Price: $13.4
Daily change: -$1.46 (-9.83%)
Daily volume: 2.1M
Capitalization: $1.6B
Industry: Biotechnology
Over the last three days, A.I.dvisor has detected that ARQT's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. A.I.dvisor backtested this indicator and found 158 similar cases, of which were successful. Based on this data, the odds of success are

ARQT in upward trend: 10-day moving average broke above 50-day moving average on November 13, 2024

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on November 13, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 16, 2024. You may want to consider a long position or call options on ARQT as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ARQT moved above its 50-day moving average on November 19, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 158 cases where ARQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARQT broke above its upper Bollinger Band on December 16, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.010) is normal, around the industry mean (14.678). P/E Ratio (0.000) is within average values for comparable stocks, (87.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). ARQT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (11.299) is also within normal values, averaging (260.407).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of treatments for dermatological diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3027 Townsgate Road
Phone
+1 805 418-5006
Employees
296
Web
https://www.arcutis.com